Fruquintinib plus paclitaxel could be a second-line treatment option for patients with gastric or gastroesophageal junction cancer, according to researchers. Fruquintinib plus paclitaxel could be a second-line treatment option for patients with gastric or GEJ cancer, according to researchers.
Fruquintinib/paclitaxel significantly improved PFS but not OS vs paclitaxel alone in the second-line treatment in patients with advanced gastric cancer.
/PRNewswire/ On January 29th, the results of the phase II study on Qilu Pharmaceutical s novel anticancer drug iparomlimab and tuvonralimab (QL1706) were.
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.